A clinical study of CL2020 in patients with epidermolysis bullosa
Phase 2
Completed
- Conditions
- Epidermolysis bullosa
- Registration Number
- JPRN-jRCT1080224498
- Lead Sponsor
- ife Science Institute, Inc.
- Brief Summary
CL2020 administration is a well-tolerated therapy and Muse cells are a potentially promising regenerative medicine for adults with severe EB.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Major inclusion criteria
Patients with epidermolysis bullosa who have any intractable ulcers
Patients aged 12 to 75 years
Female or male patients
Exclusion Criteria
Major exclusion criteria
Patients with any existing or previous malignant tumor
Female patients who are or may be pregnant or who are breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Safety after infusion of CL2020
- Secondary Outcome Measures
Name Time Method efficacy<br>efficacy after infusion of CL2020